MedTrace Logo

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-16

No results posted yet for this study

Summary

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells.

This research study involves the study drugs:

* CD79b-19 CAR T cells
* Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Conditions

Interventions

DRUG

CD79b-19 CAR T cells

Intravenous infusion

DRUG

Cyclophosphamide

Intravenous infusion

DRUG

Fludarabine

Intravenous infusion

Sponsors & Collaborators

  • Marcela V. Maus, M.D.,Ph.D.

    lead OTHER

Principal Investigators

  • Matthew Frigault, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2027-01-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06026319 on ClinicalTrials.gov